Structure Therapeutics Inc
GPCRHealthcare|Biotechnology|USA
$53.38
-1.79 (-3.25%)
Tangible Book
$20.36
Clinical Trials (10)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07400588 Aleniglipron Phase 2 in Type 2 Diabetes Mellitus | Obese, Obesity | P2 | Active | 58 | RCT, Double-blind | Aleniglipron, Placebo |
| NCT07169942 Aleniglipron Phase 2 Body Composition Study | Obesity, Overweight, or Chronic Weight Management | P2 | Active | 71 | RCT, Double-blind | aleniglipron or placebo |
| NCT06693843 A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity | Obesity, Overweight, or Chronic Weight Management | P2 | Active | 220 | RCT, Double-blind | Aleniglipron or Placebo, Aleniglipron or Placebo, Aleniglipron or Placebo, Aleniglipron, Aleniglipron, Aleniglipron, Aleniglipron |
| NCT04558450 Covid-19 Effects on Arterial Stiffness and Vascular Aging (CARTESIAN) | Covid19, Arterial Stiffness | N/A | Recruiting | 360 | Open-label | — |
| NCT07654374 A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2) | Obesity, Overweight | P3 | Not Yet Recruiting | 1,100 | RCT, Double-blind | aleniglipron, aleniglipron, aleniglipron, Placebo |
| NCT07654361 Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1) | Obesity, Overweight | P3 | Not Yet Recruiting | 3,600 | RCT, Double-blind | Aleniglipron, Placebo |
| NCT06703021 A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity | Obesity, Overweight | P2 | Completed | 85 | RCT, Double-blind | aleniglipron or placebo, aleniglipron or placebo, aleniglipron or placebo, aleniglipron or placebo |
| NCT05762471 Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes Mellitus | Overweight or Obesity, Type2 Diabetes Mellitus | P1P2 | Completed | 142 | RCT, Double-blind | GSBR-1290, Placebo |
| NCT06139055 A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants | Healthy Volunteers | P1 | Unknown | 70 | RCT, Double-blind | GSBR-1290 (Capsule/Tablet), GSBR-1290, Placebo, Placebo (Capsule/Tablet) |
| NCT05893043 A Study of Multiple Ascending Doses of GSBR-1290 in Japanese and Non-Japanese Healthy Participants | Healthy Volunteers | P1 | Completed | 18 | RCT, Double-blind | GSBR-1290 |